Drug intelligence / Profile preview

CNK-UT008

Development stage: Preclinical
Lead developer: Yizun Biotech
Modality: Cell Therapies
Administration: Intravenous

Overview

CNK-UT008 is an allogeneic T-cell therapy being developed by ST Phi Therapeutics for the treatment of autoimmune diseases, including Type 1 Diabetes, Multiple Sclerosis, and Systemic Lupus Erythematosus (SLE). The therapy is based on the company's proprietary CNK-UT platform, which utilizes chimeric NK receptor-engineered universal T-cells to recognize and eliminate pathogenic autoreactive T-cell and B-cell populations. By selectively depleting these cells, CNK-UT008 aims to reset the immune system and restore tolerance without the need for broad immunosuppression. As of early 2025, the program is in the IND-enabling stage, with an IND milestone projected for January 2025.

Other names: CNK-UT008CNK-UT-008CNK-UT 008

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CNK-UT008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNK-UT008.

Explore the full profile